Biomarin Pharmaceutical Inc. - Registered Shares

Biomarin Pharmaceutical Inc. - Registered Shares

BMRN

Get informed when a big investor buys or sells

+ Follow
Market Cap$10.58B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Biomarin Pharmaceutical Inc. - Registered SharesBiomarin Pharmaceutical Inc. - Registered Shares143.9-1%3.30.7
$95.12

Target Price by Analysts

68% upsideBiomarin Pharmaceutical - Registered Shares Target Price DetailsTarget Price
$156.91

Current Fair Value

177.1% upside

Undervalued by 177.1% based on the discounted cash flow analysis.

Share Statistics

Market cap$10.58 Billion
Enterprise Value$13.91 Billion
Dividend Yield$- (-)
Earnings per Share$1.82
Beta0.22
Outstanding Shares192,959,000

Return

Return on Equity1.15%ROE
Return on Assets0.62%
Return on Invested Capital0.76%

Valuation & Multiples

P/E Ratio143.89P/E Ratio
PEG-176.8PEG
Price to Sales3.33Price to Sales
Price to Book Ratio1.77Price to Book Ratio
Enterprise Value to Revenue4.08
Enterprise Value to EBIT182.55
Enterprise Value to Net Income190
Total Debt to Enterprise0.3
Debt to Equity0.66Debt to Equity

Revenue Sources

No data

Insider Trades

Last Earnings Call

Report Date
August 6, 2026
EPS Estimate
$0.95
Average shareholder expectation
Revenue Estimate
$932.03 M
Average shareholder expectation

Next Earnings Call

Expected Date
October 26, 2026
EPS Estimate
$-0.09
Average shareholder expectation
Revenue Estimate
$1.02 B
Average shareholder expectation

Institutional Put/Call Ratio

Market sentiment based on institutional option activity.

Put/Call Ratio0.0000▼ 36.98%
Total Calls500▼ 99.97%
Total Puts-▼ 100.00%

Institutional Ownership

Holdings and activity of institutional investors.

Ownership %1.26%▼ 100.08%
Total Invested$144.55M▼ 98.71%
Investors Holding49▼ 538.00%

ESG Score

No data

About Biomarin Pharmaceutical Inc.

3,221 employees
CEO: Jean-Jacques Bienaime

BioMarin Pharmaceutical Inc. specializes in the development and commercialization of therapeutic solutions for individuals grappling with severe and life-threatening rare diseases. Its array of market-ready products features Vimizim, an ...